What Are BMY’s Neuroscience and Immuno-Science Drugs?

How Did Bristol-Myers Squibb Fare in 2Q16? PART 7 OF 8 By Mike Benson  | Aug 19, 2016 5:04 pm EDT Neuroscience and immuno-science segments Bristol-Myers Squibb’s (BMY) neuroscience segment sales fell over 94% in 2Q16, while the immuno-science segment sales improved ~28% in 2Q16 as compared to 2Q15. The neuroscience segment is represented by the drug Abilify, while the immuno-science segment is represented by the drug Orencia. Abilify   Abilify is an antipsychotic agent used in the treatment of schizophrenia and major depressive disorders and is a part of the company’s alliance with Otsuka Pharmaceutical. Following the loss of exclusivity in the US markets, Abilify revenues have fallen by over 67% in 2Q16. The company had lost exclusivity for Abilify in the European markets in 2014, which impacted the…


Link to Full Article: What Are BMY’s Neuroscience and Immuno-Science Drugs?